Category Archives: Dermatology

Its natural for skin to thin with age. Heres how dermatologists say you should care for yours – Fortune

While aging signs like wrinkles and varicose veins are well-known, skin thinninga natural progression in which your epidermis becomes fragilegets discussed far less often. While this skin condition happens naturally with time, particularly for people of lighter skin tones, its effects can be painful and stigmatizing.

Thinning results in the skin becoming more transparent and more delicate, almost like tissuepaper. You may notice bruising more easily as a result of collagen loss around blood vessels, explains medical and cosmetic dermatologist Dr. Azadeh Shirazi. This is particularly evident on the backs of the hands and forearms, a condition called actinic purpura.

Because your skin is literally thinner, it can also tear more easily if you run into something sharp or scratch yourself with long fingernails, adds dermatologist Dr. Aanand Geria, of Geria Dermatology in New Jersey. If you have thin skin and youre prone to getting tears, then you are at risk for getting infections, he says. And the older you are, the less well your body fights off infections, and you could be in serious trouble.

Beyond the physical effects of skin thinning, the appearance of this skin condition can also affect mental well-being. People are embarrassed because they have black and blues all over their arms. These are people who are typically used to wearing skirts and short-sleeve shorts, and now they feel embarrassed to wear that stuff, says Geria, adding that many of his older patients feel this way despite the fact that skin thinning is a normal part of aging.

Skin thinning happens primarily because of a loss of two essential skin proteins, collagen and elastin, explains Geria. Collagen provides structure and support to the skin, while elastin provides elasticity. For example, people at younger ages who pull their skin away from their body will see it snap back into shape quickly. However, over time, as your elastin levels drop, it will take the skin longer to bounce back. That loss of elastin is largely sun-induced but alsoto a certain degreeis due to chronological aging, says Geria.

Loss of elastin and collagen is primarily due to U.V. radiation, or frequent exposure to the sun without protection in the form of sunscreen, hats, or long-sleeve shirts. We tend to see [skin thinning] more so in the areas that have been exposed to sun. For example, youll see thin skin on the top of your hands and the top of your forearms, more so than you would see on your belly, explains Geria.

Apart from exposure to the sun, your genetics and the amount of melanin in your skin will also influence skin thinning. Melanin, to a certain degree, does act like a low-grade skin protectant, explains Geria. So when we see thinning of the skin, that is particularly affecting people who have lighter skin. They dont have that melanin that protects them from the sun rays.

Both Geria and Shirazi agree that limiting exposure to sunlightand wearing proper sun protection when you do go outsideis the number one way to care for your skin at every stage of life. Limiting sun exposure and practicing sun protection is one of the most important ways to preserve the quality of your skin, says Shirazi. Make sure youre wearing SPF daily (even if youre working inside), sporting a hat, and limiting your exposure to sunlight.

Lifestyle factorssuch as diet and exercisemay also improve the health of your bodys largest organ. Scientists believe that when you exercise, muscles release myokines, IL-15 specifically, that may have an antiaging effect on the skin, says Shirazi. Exercise also enhances blood flow and oxygen to the skin, and when you sweat, your pores expel oil and dirt, leaving you with a healthy workout glow. Even moderate exercise can positively affect the health of your skin.

If youre already experiencing thinning skin, its still important to wear sunscreen and hats and limit your exposure to sunlight to prevent your skin from becoming even more delicate.

You should also be mindful of how you dress. Your risk of getting tears in your skin is more likely if youre wearing short-sleeve shirts and shorts. So if you wear items that cover your skin, youre gonna get that extra layer of protection so that if you run into a sharp corner of a table, its not going to tear a chunk of your skin out, says Geria. You should also consider keeping your nails short, so they cant catch in your skin.

From a skin-care standpoint, Shirazi has a few recommendations that will help strengthen your skin barrier. Using retinol-based creams help stimulate the production of collagen and hyaluronic acid, preserve the breakdown of viral skin structures, and boost circulation, she says. Shirazi also recommends trying products that contain vitamin C, which plays a role in collagen synthesis, as well as products with CoQ10, an antioxidant that positively influences the age-related cellular metabolism, she says.

You may also consider visiting a dermatologist or a cosmetic dermatologist who can make specific recommendations based on where your skin shows the most signs of thinning. For example, a skin specialist may recommend fillers that have bio-stimulative effects thathelp boost collagen production in targeted areas such as the chest, neck, and arms, Geria explains.

While youre dealing with your thinning skin, also keep in mind that youre not alone. No matter how well youve protected yourself from sun damage and taken care of your body, this part of aging is almost universaland countless other people are going through the same experience.

See the article here:

Its natural for skin to thin with age. Heres how dermatologists say you should care for yours - Fortune

Mount Sinai Awarded Prestigious $1.3 Million Grant to Expand … – Mount Sinai

The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai will expand its research training program in skin biology with support from a five-year, $1.3 million T32 grant from the National Institutes of Health (NIH) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).

The research training program in Systems Skin Biology will take a multidisciplinary approach in teaching scientists to holistically understand human physiology, health, and disease. As a recognized leader in research for skin biology and skin diseases, Mount Sinai will also become an incubator for future biomedical leaders in the field as a result of this program.

Traditional skin biology often focuses on the most obvious cells of the skin, keratinocytes, which form the structure of the epidermis and are essential for skin repair. The Systems Skin Biology program will take an interconnected approach based on the premise that neurons, immune cells, and blood vessels are just as much skin biology as traditional skin cells. Mount Sinai researchers have previously discovered new treatments for itch by studying the intersection of nerves and immune cells, and believe future studies through the Systems Skin Biology program will uncover understandings about wound repair, cancer, hair loss, vitiligo, and acne.

Science and medicine are rapidly evolving, and thus, the training itself must adapt, said co-Principal Investigator Brian S. Kim, MD, MTR, FAAD, Vice Chair of Research and Director of the Mark Lebwohl Center for Neuroinflammation and Sensation at Icahn Mount Sinai. This T32 program is truly unique in that it moves away from focusing on only one discipline, but embraces interdisciplinary training across two traditionally disparate fieldssuch as neuroscience and immunologyby using the skin and associated diseases as a model paradigm.

Dr. Kim, a renowned physician-researcher in chronic itch and inflammatory skin conditions, said the grant (number 1T32AR082315-01) will initially fund two predoctoral fellows or physician-scientists and two postdoctoral fellows or physician-scientists. It will facilitate the training of students toward PhD and/or MD/PhD degrees in intersectional skin biology, as well as training scientists and clinicians with advanced degrees to become independently funded principal investigators. In addition to dermatology, the research training program in Systems Skin Biology will include expertise drawn from across the Health System, including skin biology, immunology, neuroscience, epithelial biology, translational medicine, and stem cell biology.

This training grant will be particularly helpful for pre- and postdoctoral fellows and dermatology residents interested in bringing a new angle and new approaches to skin research, said co-Principal Investigator Sarah E. Millar, PhD, Director of the Black Family Stem Cell Institute and Senior Associate Dean for Basic Research at Icahn Mount Sinai. After training in diverse labs across Mount Sinais campus, they will be able to apply those new skills to uncover novel mechanisms in skin biology and diseases.

This T32 program is one of many steps toward our Department becoming the epicenter of innovation and a world leader in dermatology, as well as in training the future leaders and key opinion thought leaders in dermatology, said Emma Guttman-Yassky, MD, PhD, Waldman Professor of Dermatology and Immunology at Icahn Mount Sinai and Chair of Dermatology at the Mount Sinai Health System. In addition to bringing recognition of the breadth of institutional excellence in cutaneous diseases and skin biology at Mount Sinai, this training program will have an indelible impact on the future of dermatology and dermatology research for decades to come.

Mount Sinai continues to be a leader in the field of skin biology throughout New York City and the tri-state region. In 2021, the Health System established a Skin Biology and Diseases Resource-based Centerthen one of only six nationwide supported by a NIAMS grant. The Center uses technical innovations, high-end infrastructure, and computing power available at Mount Sinai to advance and support skin research; it also embeds experts in gene editing, genomics, and bioinformatics within skin research labs to break down interdisciplinary communication barriers.

About the Icahn School of Medicine at Mount Sinai

The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the eight member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population.

Ranked No. 14 nationwide in National Institutes of Health funding and in the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 full-time scientists, educators, and clinicians work within and across 34 academic departments and 44 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, and gastrointestinal and liver diseases.

Icahn Mount Sinai offers highly competitive MD, PhD, and masters degree programs, with current enrollment of approximately 1,300 students. It has the largest graduate medical education program in the country, with more than 2,600 clinical residents and fellows training throughout the Health System. In addition, more than 535 postdoctoral research fellows are in training within the Health System.

A culture of innovation and discovery permeates every Icahn Mount Sinai program. Mount Sinais technology transfer office, one of the largest in the country, partners with faculty and trainees to pursue optimal commercialization of intellectual property to ensure that Mount Sinai discoveries and innovations translate into health care products and services that benefit the public.

Icahn Mount Sinais commitment to breakthrough science and clinical care is enhanced by academic affiliations that supplement and complement the Schools programs. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai. Additionally, MSIP develops research partnerships with industry leaders such as Merck & Co., AstraZeneca, Novo Nordisk, and others.

The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem, and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinais location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally.

-------------------------------------------------------

* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Beth Israel; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.

Originally posted here:

Mount Sinai Awarded Prestigious $1.3 Million Grant to Expand ... - Mount Sinai

CU School of Medicine Resident Helped to Create Inclusive … – University of Colorado Anschutz Medical Campus

As a medical student interested in a career in dermatology, Nneamaka Ezekwe, MD, quickly realized that the textbooks particularly the collections of images of various skin conditions known as atlases didnt include photos of people with skin like hers.

Kodachrome is the word we use to describe pictures of disease that are used as a supplemental learning aid to trainees, says Ezekwe, now adermatologyresident at theUniversity of Colorado School of Medicine. These atlases have great kodachromes of diseases in lighter skin complexions. Erythema, which means redness of the skin, can be easily perceived in a lighter skin tone but may be harder to perceive and can be a subtle finding in darker skin tones. There is a spectrum of skin tones. My darker complexion is one skin tone, and there are complexions representative of Hispanic Latinos and people from the Middle East you cant box everybody into one bubble and say, This is what it looks like. We need to show the whole spectrum.

After Ezekwe graduated from medical school at the University of Mississippi and began working as a research fellow at the Henry Ford Department of Dermatology in Detroit, Michigan, she was excited to be part of an effort to create a more inclusive atlas that includes kodachromes of such conditions as vitiligo, hidradenitis suppurativa, and sarcoidosis in an array of different skin tones.

We tried to stay away from the conventional skin scale that we use as dermatologists, because it was never meant to categorize skin color. It was only supposed to be used as a scale of how easily people can burn or tan, Ezekwe says. Its not an accurate measurement of your skin complexion or the spectrum of skin colors.

For their book, The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas, editors Misty Eleryan, MD, MS, and Adam Friedman, MD, compiled more than650 images of more than 85 commonly seen dermatological conditions in an array of skin tones. Displayed side by side, the images are intended to advance education among health care practitioners and to visually teach them to recognize various skin conditions in different skin tones.

The book was released in August 2021, and the publisher sent a free copy to every trainee in every dermatology department in the country. The editors also created a free online database of inclusive dermatology images to which providers can refer.

As a research fellow, Ezekwe says, she was in the right place at the right time to be picked to work on the atlas project. She was one of the principal photographers who contributed images of various skin conditions to the book.

They picked departments of dermatology across the country that are known to have patients with a plethora of skin colors, she says. Henry Ford is a well-known dermatology department that tends to see a multitude of diverse patients because of its geographic location and the providers who are there. The editors reached out to us and said, Would you be interested in working on this atlas?

"My job was to find the patients in clinic, verify diagnosis with the provider, adequately consent,and take professional, studio-style pictures. From there, we would submit pictures and receive feedback by an in-house medical photographer weekly. We would meet regularly with the editors and advisory council to review cases and provide feedback as needed.

It was surprisingly easy to get patients to participate, she says, as many understood how photos of their conditions could help dermatologists make diagnoses in a population that has barriers to treatment. Many patients from ethnic backgrounds underrepresented in medicine have a distrust of the health care system, Ezekwe says, and many feel they arent treated with respect when they go to see a doctor. Compound those factors with conditions that are more difficult to detect in darker skin, and potentially dangerous skin conditions can get misdiagnosed or never diagnosed at all.

It's fairly easy to get shuffled around in the health care system, and then a diagnosis that could have been made in two months is now delayed to six years, she says. Patients from different ethnic groups want to serve as teachers so that their experience doesnt happen to other patients. I received that comment from many patients when I was taking their pictures.

The Full Spectrum of Dermatology is currently being used in her program at the CU School of Medicine, Ezekwe says, and she hears regularly from residents and other trainees across the country about how useful the atlas has been in their training.

'The Full Spectrum of Dermatology' was released in 2021.

The positive feedback, she says, shows that the atlas is slowly achieving its goal of making dermatology more equitable and inclusive.

Obviously, one atlas cant address disparities of health care in general, she says, but I do think this atlas can help to bridge the gap in helping to train providers to make common diagnoses. Even for primary care doctors, if they were able to pick up even one diagnosis that they didnt know, but they now know because they saw it in a book, that can help that patient, and in certain cases, lower their threshold to refer for further management to a dermatologist.

Read more from the original source:

CU School of Medicine Resident Helped to Create Inclusive ... - University of Colorado Anschutz Medical Campus

Turn Biotechnologies Introduces its Dermatology Platform to the … – Yahoo Finance

MOUNTAIN VIEW, Calif., March 30, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, announced that it will for the first time share new data for its revolutionary dermatology platform with the international regenerative aesthetic community.

Vittorio Sebastiano, Turn Biotechnologies co-founder and head of research, will share research data at the Aesthetic and Anti-aging World Congress on Friday.

Evidence-based data showing the global regenerative efficacy of Turn Bio's Epigenetic Reprogramming of Aging (ERA) technology on human skin cells will be shared at the Aesthetic and Anti-aging World Congress, the leading international conference specializing in aesthetic regenerative and anti-aging medicine.

Turn Bio's co-founder and head of research Vittorio Sebastiano, PhD, will provide insights on stem cell exhaustion and discuss how the company's ERA technology can rejuvenate cells and restore cellular function in skin. The workshopwill take place on March 31, from 9 a.m. to 10:30 a.m. CET in the Camille Blanc Auditorium at the Grimaldi Forum in Monaco.

The latest Turn Bio dermatology data will also be discussed in presentations by several dermatology key opinion leaders during scientific sessions chaired by internationally recognized experts in the field.

ABOUT TURN BIOTECHNOLOGIES

Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level and developing transformative drug delivery systems. The company's proprietary mRNA platform technology, ERA (Epigenetic Reprogramming of Aging), restores optimal gene expression by combatting the effects of aging in the epigenome. This restores cells' ability to prevent or treat disease and heal or regenerate tissue. It will help to fight incurable chronic diseases. Its eTurnaDelivery Platform uses unique formulations to precisely deliver cargo to specific organs, tissues, and cell types.

The company is completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, and developing therapies for ophthalmology, osteo-arthritis, and the muscular system. For more information, see http://www.turn.bio.

Story continues

FOR MORE INFORMATION, CONTACT:

Jim Martinez, rightstorygroupjim@rightstorygroup.comor (312) 543-9026

(PRNewsfoto/Turn Biotechnologies, Inc.)

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/turn-biotechnologies-introduces-its-dermatology-platform-to-the-european-aesthetic-community-at-amwc-301785512.html

SOURCE Turn Biotechnologies, Inc.

Read more:

Turn Biotechnologies Introduces its Dermatology Platform to the ... - Yahoo Finance

AAD Posters Address Misconceptions, Concerns Regarding … – AJMC.com Managed Markets Network

A majority of research has shown that biosimilars are highly similar to their originator product in terms of safety and efficacy. Two posters presented at the American Academy of Dermatology (AAD) annual meeting evaluated misconceptions about biosimilars in the dermatology community and addressed concerns around the use of biosimilars in psoriasis with a review of the data.

The first poster reviewed the biosimilar approval process to clarify misconceptions that dermatologists have about biosimilars.1 Dermatologists have approached biosimilar medicines with caution, the researchers wrote.

A recent Cardinal Health report2 corroborated the sentiment that dermatologists are hesitant to switch to biosimilars. According to the report, only 31% of dermatologists considered themselves very familiar with biosimilars compared with 81% of gastroenterologists, 76% of rheumatologists, and 36% of ophthalmologists. Dermatologists were also the most likely compared with the other specialists to say they were not very familiar (13%).

The authors of the AAD poster used a PubMed search to identify studies on the molecular design, preclinical and clinical testing requirements, and approval processes of biosimilars. They described how the complexity of biologics means that even batches of innovator biologics can vary during preclinical testing.

Biosimilars undergo strict preclinical testing and must demonstrate near-similarity to the current originator product in quality factors such as receptor binding and pharmacokinetics, the researchers explained.

While clinical testing is less stringent for a biosimilar compared with the originator product, the purpose of the clinical testing is to confirm the safety and efficacy of the biosimilar. Then, the use of extrapolation allows for biosimilars to be approved for all indications of the originator product without further testing. As a result, the emphasis of biosimilar product testing is on preclinical rather than clinical testing, the authors noted.

Physicians who recognize that biologics are too complex to duplicate, and who desire indication-specific clinical data on biosimilars, might be satisfied knowing biosimilars provide more evidence of similarity than we have for different batches of the innovator product, they concluded. Regulations that are more stringent for biosimilars than for different batches of innovator products may not be logical.

In the second poster, the researchers addressed concerns about the use of biosimilars approved to treat psoriasis using extrapolated evidence from other diseases.3

The researchers compared efficacy/effectiveness, safety, and drug survival of biosimilars to treat plaque psoriasis with originator products. They used data from 13 randomized controlled trials (RCTs) and 3 cohort studies. Of the RCTs, 10 were for adalimumab, 2 were etanercept, and 1 was infliximab. Of the cohort studies, 1 was adalimumab, 1 was etanercept, and 1 was both etanercept and infliximab.

There were 11 trials that compared biosimilars with the originator in patients who had never been on the originator product (initiators), and 9 trials analyzed switching from the originator product to the biosimilar (switchers). The initiator trials all had similar rates of 75% improvement in Psoriasis Area and Severity Index, as well as similar adverse events (AEs) by week 16 and the switched trials also had similar outcomes by week 52.

One of the cohort studies reported more AEs among the group of adalimumab patients switching from originator to the biosimilar, although the other 2 cohort studies showed no significant differences in safety and effectiveness.

The majority of available evidence suggests similarities between biosimilars and originators, the researchers concluded. Future pharmacovigilance studies are needed to evaluate the long-term, real-world use of biosimilars for psoriasis treatment.

References

1. Patel P, Purvis C, Hamid R, Feldman S. Biosimilars in dermatology: understanding testing and addressing misconceptions. Presented at: AAD Annual Meeting; March 17-21, 2023; New Orleans, LA. Poster 41465. https://eposters.aad.org/abstracts/41465

2. 2023 Biosimilars Report. Cardinal Health. February 22, 2023. Accessed March 28, 2023. https://www.cardinalhealth.com/content/dam/corp/web/documents/Report/cardinal-health-biosimilars-report-2023.pdf

3. Phan DB, Warren RB, Lunt M, Yiu ZZN. Biosimilars in the treatment of psoriasis a systematic review of evidence from randomized controlled trials and real-world data. Presented at: AAD Annual Meeting; March 17-21, 2023; New Orleans, LA. Poster 42621. https://eposters.aad.org/abstracts/42621

Link:

AAD Posters Address Misconceptions, Concerns Regarding ... - AJMC.com Managed Markets Network

5 Perspectives on Laser Treatment in Dermatology – Dermatology Times

Interested in finding out what is new, trending, and up-and-coming in the world of laser therapy in dermatology? Review these 5 articles from the Maui Derm Hawaii 2023 conference coverage earlier this year.

/AdobeStock

Suneel Chilukuri, MD, discussed a Maui Derm Hawaii 2023 session called Lasers and Energy Devices Used to Treat Medical Problems Whats New in 2023. In the session, a group of experts, including Chilukuri, discussed using lasers and other similar devices to treat dermatologic conditions such as acne, cutaneous lesions, scars, and pigment disorders.

Lawrence Eichenfield, MD, discussed the use of several laser and laser-based therapies for the treatment of acne vulgaris in adolescents at his Maui Derm Hawaii 2023 session.

Several current laser therapy options for acne include blue light, pulsed dye laser, Nd: YAG (long-pulsed, Q-switched, combination), erbium laser resurfacing therapies, intense pulsed light, photodynamic therapy, solid-state fractional 589/1319 nm laser, and 1726-nm laser systems.

Ilona Frieden, MD, discussed the future of laser treatments in port wine stains at her Maui Derm Hawaii 2023 session.

"Part 3 of my talk relates to a remarkable revolution that happened in medicine. And that's the advent of next-generation sequencing, which allowed us to begin to unravel the genomics of so many disorders including port wine stain birthmarks. That occurred in the past 2 decades, but mostly starting around 2010, Frieden said. What happened with that was that we had really no idea what caused them, we knew it must be some developmental error that caused this process of the blood vessels not forming correctly. But that was about it. We knew the causes of the vast majority of them, we do know the causes, and that was a real revelation.

David Laub, MD, discussed the use of laser treatment in cosmetic procedures in his Maui Derm Hawaii 2023 session Whats My Treatment.

In the session, Laub and a panel of experts discussed several real-world patient cases. Dermatologists in the surgical and aesthetic spaces assessed each case to determine which treatment (energy-based devices, lasers, fillers, injectables, topical medications) would be recommended. Then, the panelists revealed which treatment was used and why.

The second case could be in the same arena pigmentation, where a different colleague will go and maybe treat it with lasers or some other device, the same particular problem so that the audience can get a very strong sense of the different modalities that can be used for a particular problem, whether it be pigmentation, wrinkles, or reversing sun damage, in the form of texture, Laub said.

Suzanne Kilmer, MD, discussed the future of laser and energy-based devices in dermatologic treatment in her Maui Derm Hawaii 2023 session Lasers, Lights, Radiofrequency, Photodynamic Therapy and More.

We also talk about acne and ways to target acne with lasers, that's a booming field right now, Kilmer said. There are new lasers in the 1720 nanometer range that target the sebaceous glands because they have fat in them and that wavelength is absorbed by fat. So that's kind of a big newer one that's coming out.

More here:

5 Perspectives on Laser Treatment in Dermatology - Dermatology Times

Making Connections Between Psychiatry and Dermatology – Psychiatric Times

Various studies encounter a psychiatric condition in 1 out of 3 dermatology patients. In collaboration with Dermatology Times, Psychiatric Times connected with George Kroumpouzos, MD, PhD, FAAD, a dermatologist who combines psychodermatology with clinical and cosmetic dermatology in his practice.

In this episode of An Appointment With, Kroumpouzos discusses the connections between psychiatric and dermatologic conditions, as well as the ways psychiatrists and dermatologists can work together to help patients with psychiatric and dermatologic comorbidities.

Dr Kroumpouzos is director of GK Dermatology, a clinical associate professor of dermatology at Brown University, and a professor of dermatology and collaborator at Jundia Medical School in So Paulo, Brazil.He combines clinical, cosmetic, and psychodermatology in his practice.

See the original post:

Making Connections Between Psychiatry and Dermatology - Psychiatric Times

Dermatology Associates of Rochester on Top Workplaces 2023 list – Democrat & Chronicle

Gregory Burnett| Rochester Democrat and Chronicle

Laura Hellaby, human resources director for Dermatology Associates of Rochester, spoke about her workplace.

Its a unique practice because it is value-driven no position within the company is more important to the organization than another.

Our leadership prides itself on having an open-door policy where they encourage and are interested in innovative ideas or ideas from any team members on how to improve efficiency or process, Hellaby said. This feedback is then used to help make sure the practice is always improving, innovating, and actively working to be the best in all areas of service. However, we also stand out from other places because of the variety in which we can offer our patients a transformative, one-stop location for all things dermatology related.

Dermatology Associates is a fast paced, collaborative, and energetic workplace. Management stresses the need to foster this environment by encouraging open communication.

We seek to enrich the lives of our patients, employees, and community members through the delivery of unparalleled, individualized care with attention to health, wellness, and education, Hellaby said.

2023 Rochester Top Workplaces: 2023 Rochester Top Workplaces: Complete list of all 79 winners

More: Heres how Rochester's Top Workplaces were determined for 2023

Ensuring team members are equipped with tools for success is always vital to productivity.

This Top Workplace invested in additional education opportunities for its workers. Initiatives include lunch-and-learn-enrichment days and retreats. A system called one-on-one meetings brings together staff to discuss challenges, set goals, and run through practice scenarios.

Many benefits are available for employees to enjoy.

We typically invest over $40,000 per year on continuing education opportunities because we know how important it is to continue their development, Hellaby said. Our staff [members] have the opportunity to receive and experience wrinkle-reducing treatments, dermal filler, laser, and CoolSculpting treatments multiple times throughout the year a perk worth $5,000 to $15,000 per person. Our staff [members] typically receive around $125,000 worth of complimentary cosmetic treatments. Our clinical team enjoys a four-day work week. We also offer a full benefits package, including medical, dental, vision, life insurance, an employee assistance program, and a 401(k) plan with employer contribution. Having a work/ life balance is promoted consistently. We want people to come to work happy and leave happy. Our one-on-one meeting is essential because it gives employees a platform to address their issues.

Read the original here:

Dermatology Associates of Rochester on Top Workplaces 2023 list - Democrat & Chronicle

Biofrontera Inc. Makes Transformative Investment in Its’ Dermatology … – BioSpace

WOBURN, MA / ACCESSWIRE / March 27, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it is executing on the company's stated plans to invest in and meaningfully grow its' salesforce in 2023.

"With this investment in the salesforce, Biofrontera is taking an important step forward in our growth strategy," stated Erica Monaco, Chief Executive Officer of Biofrontera Inc. "The success of our FDA-approved therapy for actinic keratosis (AK), Ameluz-PDT, is directly related to our ability to educate dermatologists and patients about AK and the potential health benefits of our therapy. The strengthening of our sales effort will greatly improve our reach in key dermatology markets across the United States and position us well to further penetrate this large opportunity."

"We achieved record revenues and grew market share in 2022 with fewer sales people and territories than we had pre-COVID - an example of the capabilities of our current team," continued Ms. Monaco. "Today, we are adding a new sales region and growing the salesforce by almost 30% to now cover 40 territories. We are also adding a combined 140 years of healthcare and dermatology experience to our existing customer coverage. Biofrontera is at an important, business inflection point and we are confident that this expansion of the salesforce will enable us to accelerate growth and continue our market share gains in 2023 and beyond."

About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit http://www.biofrontera-us.com.

Forward-looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the growth strategy for Biofrontera Inc.'s (the "Company") Ameluz-PDT, improved market opportunities, educational outreach efforts, growth of the Company's salesforce and its sales territories and the impact of expanding the Company's salesforce on growth. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, including, but not limited to, the impact of any extraordinary external events; any changes in the Company's relationship with its licensors; the ability of the Company's licensors to fulfill their obligations to the Company in a timely manner; the Company's ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company's ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company's licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz in combination with BF-RhodoLED in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz in combination with BF-RhodoLED is consistent with the Company's expectations; the Company's ability to comply with public company requirements; the Company's ability to regain compliance with Nasdaq continued listing standards, the Company's ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and other factors that may be disclosed in the Company's filings with the SEC, which can be obtained on the SEC website at http://www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

Contact:

Biofrontera Investor Relationsir@bfinc.com

SOURCE: Biofrontera Inc.

View source version on accesswire.com:https://www.accesswire.com/745901/Biofrontera-Inc-Makes-Transformative-Investment-in-Its-Dermatology-Salesforce

See the article here:

Biofrontera Inc. Makes Transformative Investment in Its' Dermatology ... - BioSpace